A Study Investigating the Pharmacokinetic and Pharmacodynamic Properties and Safety and Tolerability of Three Formulations of NNC0471-0119 When Administered as One Bolus in a Continuous Subcutaneous Insulin Infusion Regimen in Participants With Type 1 Diabetes
Latest Information Update: 20 Oct 2022
At a glance
- Drugs NNC 0471-0119 (Primary) ; Insulin aspart
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
Most Recent Events
- 14 Oct 2022 Status changed from active, no longer recruiting to completed.
- 15 Aug 2022 Planned End Date changed from 12 Oct 2022 to 9 Sep 2022.
- 15 Aug 2022 Planned primary completion date changed from 28 Sep 2022 to 30 Aug 2022.